



March 5, 2012

ImmunoCellular Therapeutics to Present at Cowen and Company's 32nd Annual Health Care Conference

LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Cowen and Company's 32nd Annual Health Care Conference on Monday, March 5th, at 2:10 p.m., on the 4th floor, Salon C of the Marriot Hotel in Boston, Massachusetts. The presentation will be webcast following registration at the web address below: <http://wsw.com/webcast/cowen6/imuc/>.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics (OTC.BB: IMUC.OB - News) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that any patents issued covering IMUC's vaccine technology will not provide significant commercial protection for IMUC's technology or products; the risk that licensed technology may infringe the proprietary rights of third parties; the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need for substantial additional capital to fund development of ICT-140 through to commercialization; and the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

ImmunoCellular Therapeutics, Ltd.
CEOcast, Inc.
James Young
Investor Relations
Tel: (212) 732-4300
Email: jyoung@ceocast.com

Source: ImmunoCellular Therapeutics, Ltd.